Summary of Screening Patterns.

<p>IST—immunosuppressive therapy</p><p>Summary of Screening Patterns.</p

Physician ability to identify patients at high risk of chronic HBV infection based on country of origin.

<p>Patients originating from areas with greater than an intermediate rate (≥2) of chronic HBV infection, as determined by the CDC [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0120749#pone.0120749.ref016" target="_blank">16</a>], were identified through the patient questionnaire. This figure illustrates the proportion of these patients who were correctly identified by their treating physician as being at high risk of HBV reactivation due to their country of origin.</p

Summary of current guidelines regarding HBV screening.

<p>*As per the AASLD guidelines, patients can be tested with anti-HBc alone provided that patients who test positive are further tested for HBsAg and anti-HBs to differentiate infection from immunity.</p><p>Summary of current guidelines regarding HBV screening.</p

Demographics of Physician Respondents.

<p>Demographics of Physician Respondents.</p

Screening practices of physicians prior to immunosuppressive therapy.

<p>A) The proportion of patients identified to merit screening for HBV prior to immunosuppressive therapy in each specialty are shown. This is contrasted with the proportion of patients requiring TB screening before biologic DMARDs (rheumatology) and cardiac testing prior to anthracycline-based chemotherapy (hematologists/oncologists). B) The rates of planned screening are contrasted with the actual rate of HBV screening for HBV prior to immunosuppressive therapy for all patients and for the sub-group of patients from HBV-endemic countries.</p